Molecular therapies in hepatocellular carcinoma: what can we target?

Molecular mechanism of hepatitis B virus-induced hepatocarcinogenesis. World J Gastroenterol (2014) 1.17

Recent Advances in Tumor Ablation for Hepatocellular Carcinoma. Liver Cancer (2015) 1.08

Genetic and epigenetic aspects of initiation and progression of hepatocellular carcinoma. World J Gastroenterol (2015) 0.97

miR-125a inhibits the migration and invasion of liver cancer cells via suppression of the PI3K/AKT/mTOR signaling pathway. Oncol Lett (2015) 0.85

Mechanisms of hepatocellular carcinoma and challenges and opportunities for molecular targeted therapy. World J Hepatol (2015) 0.84

Angiopoietin 2 as a therapeutic target in hepatocellular carcinoma treatment: current perspectives. Onco Targets Ther (2014) 0.84

LLL12, a novel small inhibitor targeting STAT3 for hepatocellular carcinoma therapy. Oncotarget (2015) 0.82

The transcriptomic G1-G6 signature of hepatocellular carcinoma in an Asian population: Association of G3 with microvascular invasion. Medicine (Baltimore) (2016) 0.75

A Hybrid Chalcone Combining the Trimethoxyphenyl and Isatinyl Groups Targets Multiple Oncogenic Proteins and Pathways in Hepatocellular Carcinoma Cells. PLoS One (2016) 0.75

Sorafenib in advanced hepatocellular carcinoma. N Engl J Med (2008) 54.30

Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med (2003) 35.39

Angiogenesis in cancer and other diseases. Nature (2000) 28.28

Management of hepatocellular carcinoma. Hepatology (2005) 27.42

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol (2008) 23.93

ras genes. Annu Rev Biochem (1987) 22.59

Hepatocellular carcinoma. Lancet (2003) 22.54

ras oncogenes in human cancer: a review. Cancer Res (1989) 22.03

Hypoxia--a key regulatory factor in tumour growth. Nat Rev Cancer (2002) 20.51

Hepatocellular carcinoma. N Engl J Med (2011) 19.40

EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol (2012) 16.93

Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature (1993) 15.70

The biology of vascular endothelial growth factor. Endocr Rev (1997) 13.70

Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev (2007) 13.05

Cell signaling by receptor tyrosine kinases. Cell (2010) 12.39

Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology (2003) 11.55

Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology (2012) 10.00

Small GTP-binding proteins. Physiol Rev (2001) 9.52

Caught up in a Wnt storm: Wnt signaling in cancer. Biochim Biophys Acta (2003) 7.85

Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta (2006) 7.33

Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis (2010) 5.85

Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology (2004) 5.83

The primary structure of MEK, a protein kinase that phosphorylates the ERK gene product. Science (1992) 5.55

Genotype-phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC. Hepatology (2006) 5.46

The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition. Oncogene (2007) 5.14

Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology (2008) 4.73

Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis (2005) 4.51

The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol (2006) 4.17

Ras recruits Raf-1 to the plasma membrane for activation by tyrosine phosphorylation. EMBO J (1995) 4.17

Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis (2007) 3.75

Loco-regional treatment of hepatocellular carcinoma. Hepatology (2010) 3.59

Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy? Nat Rev Cancer (2010) 3.59

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. Oncotarget (2011) 3.43

Targeted therapies for hepatocellular carcinoma. Gastroenterology (2011) 2.85

GAPs galore! A survey of putative Ras superfamily GTPase activating proteins in man and Drosophila. Biochim Biophys Acta (2003) 2.71

Mechanisms of regulating the Raf kinase family. Cell Signal (2003) 2.58

Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design. J Hepatol (2012) 2.53

Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. Gastroenterology (2008) 2.46

Down-regulation of Notch-1 contributes to cell growth inhibition and apoptosis in pancreatic cancer cells. Mol Cancer Ther (2006) 2.44

Genetics of hepatocellular tumors. Oncogene (2006) 2.43

Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy. Expert Opin Ther Targets (2012) 2.42

Angiogenesis in liver disease. J Hepatol (2008) 2.31

Obesity, inflammation, and liver cancer. J Hepatol (2011) 2.09

beta-Catenin signaling in biological control and cancer. J Cell Biochem (2007) 1.89

Notch signaling: emerging molecular targets for cancer therapy. Biochem Pharmacol (2010) 1.54

Pathogenesis of hepatocellular carcinoma and molecular therapies. Curr Opin Gastroenterol (2009) 1.52

Wnt/Frizzled signaling in hepatocellular carcinoma. Front Biosci (2006) 1.50

Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: systematic review and meta-analysis. Br J Cancer (2009) 1.38

GTPases and T cell activation. Immunol Rev (2003) 1.36

Small-molecule modulators of the Sonic Hedgehog signaling pathway. Mol Biosyst (2009) 1.35

Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib. J Hepatol (2012) 1.26

Staging and current treatment of hepatocellular carcinoma. Radiographics (2005) 1.23

Blockade of IGF-1 receptor tyrosine kinase has antineoplastic effects in hepatocellular carcinoma cells. Biochem Pharmacol (2006) 1.21

The Ras/Raf/MAPK pathway. J Thorac Oncol (2006) 1.16

PKI-587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf/MAPK pathways synergistically inhibit HCC cell proliferation. J Surg Res (2011) 1.15

Overexpression of VEGF is associated with positive p53 immunostaining in hepatocellular carcinoma (HCC) and adverse outcome of HCC patients. J Surg Oncol (2008) 1.13

Current status of molecularly targeted therapy for hepatocellular carcinoma: clinical practice. Int J Clin Oncol (2010) 0.94

Farnesyl transferase inhibitors for patients with lung cancer. Clin Cancer Res (2004) 0.89

The role of PI3K/mTOR inhibition in combination with sorafenib in hepatocellular carcinoma treatment. Anticancer Res (2012) 0.88

Effects of insulin-like growth factors-IR and -IIR antisense gene transfection on the biological behaviors of SMMC-7721 human hepatoma cells. J Gastroenterol Hepatol (2003) 0.82

Farnesyl transferase inhibitors: a major breakthrough in anticancer therapy? Naples, 12 April 2002. Anticancer Drugs (2002) 0.80

Alpha-fetoprotein and tumour size are associated with microvascular invasion in explanted livers of patients undergoing transplantation with hepatocellular carcinoma. HPB (Oxford) (2010) 1.05

Predictors of surgical site infection after liver resection: a multicentre analysis using National Surgical Quality Improvement Program data. HPB (Oxford) (2011) 0.97

Synergistic inhibition of HCC and liver cancer stem cell proliferation by targeting RAS/RAF/MAPK and WNT/β-catenin pathways. Anticancer Res (2014) 0.91

An in vitro study of liposomal curcumin: stability, toxicity and biological activity in human lymphocytes and Epstein-Barr virus-transformed human B-cells. Int J Pharm (2008) 0.90

Seatbelt injury resulting in functional loss of a transplanted kidney. Prog Transplant (2008) 0.88

Cyclosporin A up-regulates and activates protein kinase C-zeta in EBV-infected and EBV-transformed human B-cells. J Surg Res (2008) 0.84

Arteriovenous malformation of the pancreas: A case report and review of literature. Int J Angiol (2008) 0.83

Transjugular intrahepatic portosystemic shunt to keep vein open. Liver Transpl (2009) 0.82

Predicting dry weight in patients with ascites and liver cirrhosis using computed tomography imaging. Hepatogastroenterology (2010) 0.81

Cyclosporin A-induced lipid and protein oxidation in human B-cells and in Epstein-Barr virus-infected B-cells is prevented by antioxidants. J Invest Surg (2008) 0.80

The use of Dacron graft for cavo-cavostomy in orthotopic liver transplantation. Transplantation (2008) 0.80

Risk factors for 30-day readmissions after hepatectomy: analysis of 2444 patients from the ACS-NSQIP database. J Gastrointest Surg (2014) 0.79

Vaginal varices with massive hemorrhage in a patient with nonalcoholic steatohepatitis and portal hypertension: Successful treatment with liver transplantation. Liver Transpl (2008) 0.77

Importance of local infection in hepatic artery pseudoaneurysms. Liver Transpl (2008) 0.75

Duodenal drainage during pancreas transplantation. J Am Coll Surg (2007) 0.75

Thrombectomy and cavocavostomy for inferior vena cava thrombosis and torsion after piggyback liver transplantation. Liver Transpl (2012) 0.75

Hepatobiliary mucinous cystadenoma resulting in biliary obstruction. Am Surg (2015) 0.75

Successful open pulmonary embolectomy for acute massive pulmonary embolism in a recent kidney transplant recipient. Ann Transplant (2008) 0.75

A pharmacoeconomic analysis of liver transplant charges. Prog Transplant (2007) 0.75

Direct intranodal lymphangiography for recurrent chylous ascites following liver-kidney transplantation. Liver Transpl (2014) 0.75

Neuroendocrine Liver Metastasis: Transplant as Part of Multimodality Liver-Directed Therapy-Reply. Arch Surg (2012) 0.75

Perioperative and long-term outcomes in octogenarians after kidney transplantation: the US perspective
. Clin Nephrol (2016) 0.75

Liver transplantation for the treatment of nonresectable metastatic duodenal paraganglioma. Transpl Int (2006) 0.75